Timothy Furlong, MD
Psychiatry · Athens, TXNPI 1629044557
Payments from drug & device makers
Across 338 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$930
- Neurocrine Biosciences, Inc.$757
- Alkermes, Inc.$633
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$593
- Sunovion Pharmaceuticals Inc.$565
- Otsuka America Pharmaceutical, Inc.$522
- plus $2K from 18 others
What the payments were for
- Food & beverage$6,24199%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $930 |
| Neurocrine Biosciences, Inc. | 35 | $757 |
| Alkermes, Inc. | 36 | $633 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 28 | $593 |
| Sunovion Pharmaceuticals Inc. | 38 | $565 |
| Otsuka America Pharmaceutical, Inc. | 25 | $522 |
| Vanda Pharmaceuticals Inc. | 20 | $490 |
| Johnson & Johnson | 20 | $411 |
| Teva Pharmaceuticals USA, Inc. | 21 | $328 |
| Lundbeck LLC | 13 | $253 |
| E.r. Squibb & Sons, L.L.C. | 14 | $210 |
| Axsome Therapeutics, Inc. | 8 | $173 |
| Indivior Inc. | 6 | $133 |
| Corium, LLC | 3 | $63 |
| Almatica Pharma LLC | 3 | $50 |
| Eisai Inc. | 2 | $33 |
| Xeris Pharmaceuticals, Inc. | 1 | $25 |
| Neuronetics, Inc. | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13 |
How this compares
$6,293 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 140 | $205,335 |
| IngrezzaValbenazine Tosylate | 21 | $182,306 |
| Invega SustennaPaliperidone Palmitate | 53 | $170,043 |
| CaplytaLumateperone Tosylate | 65 | $115,765 |
| Abilify MaintenaAripiprazole | 28 | $79,895 |
| RexultiBrexpiprazole | 32 | $44,569 |
| AristadaAripiprazole Lauroxil | 12 | $40,948 |
| Risperdal ConstaRisperidone Microspheres | 13 | $32,541 |
| GeodonZiprasidone Hcl | 12 | $31,765 |
| BelsomraSuvorexant | 63 | $27,178 |
| Chlorpromazine Hcl | 63 | $9,686 |
| Hydroxyzine Hcl | 256 | $8,002 |
| Quetiapine Fumarate | 354 | $7,410 |
| Gabapentin | 281 | $6,129 |
| Aripiprazole | 202 | $5,999 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $930 | $205,335140 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $411 | $202,58466 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $757 | $182,30621 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $522 | $124,46560 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $593 | $115,76565 claims |
| Alkermes, Inc.Aristada | $633 | $40,94812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $13 | $4,26411 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $328 | $2,68852 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Athens
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$5.9M
- Marshall LucasThe Woodlands$4.8M
- Sejal MehtaPlano$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.